Background Patients with COVID-19 infection are commonly reported to have an increased
risk of venous thrombosis. The choice of anti-thrombotic agents and doses are currently …

Introduction: Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection resulting in COVID-19 disease is associated with widespread inflammation and a …

Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous
thromboembolism events (VTE). This study performed a systematic review in …

Background High incidence of asymptomatic venous thromboembolism (VTE) has been
observed in severe COVID‐19 patients, but the characteristics of symptomatic VTE in …

Background: Coagulopathy associated with COVID-19 infection and venous
thromboembolism (VTE) have emerged as significant contributors to morbidity among …

Background: Emerging evidence shows that coronavirus disease 2019 (COVID-19) is
commonly complicated by coagulopathy, and venous thromboembolism (VTE) is considered …

Background We aimed to identify the prevalence and predictors of venous
thromboembolism (VTE) or mortality in hospitalized coronavirus disease 2019 (COVID-19) …

Background Antithrombotic guidance statements for hospitalized patients with coronavirus
disease 2019 (COVID‐19) suggest a universal thromboprophylactic strategy with potential to …

Background Sources of heterogeneity in venous thromboembolism (VTE) risk in COVID-19
are unclear and comparisons to other viruses are lacking. Objectives To describe VTE risk in …

Importance Patients hospitalized with COVID-19 have higher rates of venous
thromboembolism (VTE), but the risk and predictors of VTE among individuals with less …